Effect of VMAT2 inhibition during subacute MPTP treatment
| VMAT2 Inhibitor | MPTP | DA Content |
|---|---|---|
| mg/kg | μg/g tissue | |
| Experiment 12-a | ||
| Saline (3) | Saline | 10.1 ± 0.6 |
| Ro 4-1284 (4) | Saline | 10.6 ± 0.2 |
| Saline (7) | 30 | 2.7 ± 0.52-c |
| Ro 4-1284 (3) | 30 | 0.6 ± 0.12-c 2-d |
| Experiment 22-b | ||
| Saline (3) | Saline | 12.0 ± 1.3 |
| Ro 4-1284 (5) | Saline | 12.3 ± 0.8 |
| Reserpine (3) | Saline | 10.0 ± 2.0 |
| Saline (4) | 30 | 3.8 ± 0.62-c |
| Ro 4-1284 (3) | 30 | 2.1 ± 0.52-c |
| Reserpine (3) | 30 | 3.7 ± 0.52-c |
Mice were treated as described in the footnotes. Results are the mean striatal DA content ± S.E. for the number of mice designated in parentheses.
↵2-a Mice were treated for 5 days; a single i.p. injection of Ro 4-1284 (10 mg/kg) was administered 15 min before a single i.p. injection of MPTP (30 mg/kg). Mice were sacrificed 7 days later.
↵2-b Mice were treated for 9 days; Ro 4-1284 and MPTP treatment were as in Exp to 1. A single injection of reserpine (2 mg/kg) was given 24 h before MPTP treatment. Mice were treated for 9 days and sacrificed 28 days later.
↵2-c P < .05 versus saline/saline controls.
↵2-d P < .05 versus saline/MPTP-treated group.